Auroraseq Auroraseq

Molecular pathology laboratories need to provide prompt assessments of the molecular biomarkers present in tumor samples to allow informed treatment decisions. AuraSeq uses next-generation sequencing (NGS) technology enabling the testing of multiple biomarkers, such as somatic variants in oncogenic driver genes, in a single assay. 

AuraSeq-Comprehensive Panel

The AuraSeq-Comprehensive Panel is a highly multiplexed assay based on a next-generation sequencing platform. AuraSeq-Comprehensive identifies clinically relevant alterations in 500 cancer-related genes, including base pair substitutions, small insertions and deletions in thousands of mutational hotspots, as well as copy number variations, intergenic and intragenic fusions, and genomic signatures, allowing physicians to expand treatment options to include most FDA-approved targeted therapies.

AuraSeq-Solid Tumor

The AuraSeq-Solid Tumor panel, a highly multiplexed assay based on an NGS platform, allows the identification of drug targets in different genes simultaneously, assisting physicians in selecting personalized therapies.

AuraSeq-Fusions panel

AuraSeq-Fusions panel, a highly multiplexed assay based on an NGS platform, allows the simultaneous identification of drug targets caused by different genomic abnormalities, assisting physicians in selecting personalized therapeutic treatments.

For further information, please contact:

Jorge Almenara, Ph.D.
General Manager
Bernhardt Laboratories
P: 804.551.1598

Info_apdivision@sonichealthcareusa.com

 

Brad Bernhardt
Director of Product Development
Anatomic Pathology Division, Sonic Healthcare USA
P: 904.813.3088

Info_apdivision@sonichealthcareusa.com

Reference:  Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.